Europe let its antibiotics drift to China. Sandoz is asking Brussels to fight back

For most of the past two decades, Europe treated the antibiotic as the most disposable thing in its medicine cabinet: cheap, generic, endlessly available, and therefore not worth making at home. That quiet assumption is now the subject of a formal complaint in Brussels.

Offshoring penicillin was never really a decision about chemistry. It was a decision about price. Generic antibiotics carry margins so thin that European producers spent years closing plants and conceding the business to lower-cost rivals abroad, on the comfortable theory that a global market would always refill the shelf. The pandemic-era scramble for the most basic drugs was the first sign that the shelf could empty. The continent is only now treating that as a structural fact rather than a bad season.

Sandoz, the Swiss generic-drug maker spun out of Novartis, has decided to force the question. The company has filed a draft anti-dumping complaint with the European Commission over Chinese imports of amoxicillin, the workhorse penicillin prescribed to children and adults across the continent. Its case is less about one molecule than about a pattern it describes as market distortion: sustained below-cost pricing, state subsidies, and a deliberate concentration of global capacity inside a single country.

The numbers behind the filing are the uncomfortable part. Up to 90 percent of the active ingredients in the world’s antibiotics are now produced outside Europe, and China supplies the large majority of what the European Union actually consumes. Sandoz says it runs the last major vertically integrated penicillin network on the continent, anchored at its site in Kundl, Austria, a plant that has just marked its 80th anniversary and whose long-term survival is the unstated subject of the complaint.

The timing is not accidental. Brussels has spent months drafting a Critical Medicines Act meant to claw back production of strategically important drugs, and a live trade case gives that ambition teeth. “Safeguarding antibiotic supply is not only a health policy issue, but a question of economic security and strategic trade policy,” chief executive Richard Saynor said. “Europe must act now to safeguard independent supply in years to come.”

The deeper question is whether a continent that taught itself to import its cheapest medicines can still afford to make them. A complaint filed in Brussels cannot answer that. The next winter shortage will.